Related references
Note: Only part of the references are listed.Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
A. S. Coates et al.
ANNALS OF ONCOLOGY (2015)
Anti-programmed cell death protein-1/ligand-1 therapy in different cancers
B. Homet Moreno et al.
BRITISH JOURNAL OF CANCER (2015)
Tumor associated PD-L1 expression pattern in microscopically tumor positive sentinel lymph nodes in patients with melanoma
Ahmad A. Tarhini et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2015)
Anti-PD-L1 for metastatic triple-negative breast cancer
Josefine Gibson
LANCET ONCOLOGY (2015)
PD-L1 expression is common and indicates poor prognosis
Clemens Thoma
Nature Reviews Urology (2015)
Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK
Idit Sagiv-Barfi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Gene expression patterns through oral squamous cell carcinoma development: PD-L1 expression in primary tumor and circulating tumor cells
Joao Paulo Oliveira-Costa et al.
ONCOTARGET (2015)
PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy
Francois Bertucci et al.
ONCOTARGET (2015)
Prognostic and predictive value of PDL1 expression in breast cancer
Renaud Sabatier et al.
ONCOTARGET (2015)
Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer
Michael T. Barrett et al.
ONCOTARGET (2015)
PDL1 expression is an independent prognostic factor in localized GIST
Francois Bertucci et al.
ONCOIMMUNOLOGY (2015)
Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer
S. Muenst et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
Programmed Cell Death 1 (PD-1) and Its Ligand (PD-L1) in Common Cancers and Their Correlation with Molecular Cancer Type
Zoran Gatalica et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2014)
In Situ Tumor PD-L1 mRNA Expression Is Associated with Increased TILs and Better Outcome in Breast Carcinomas
Kurt A. Schalper et al.
CLINICAL CANCER RESEARCH (2014)
PD-L1 Expression in Triple-Negative Breast Cancer
Elizabeth A. Mittendorf et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
A. Goldhirsch et al.
ANNALS OF ONCOLOGY (2013)
The relationship between components of tumour inflammatory cell infiltrate and clinicopathological factors and survival in patients with primary operable invasive ductal breast cancer
Z. M. A. Mohammed et al.
BRITISH JOURNAL OF CANCER (2012)
Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses
Andreas Stang
EUROPEAN JOURNAL OF EPIDEMIOLOGY (2010)
Inhibitory B7-family molecules in the tumour microenvironment
Weiping Zou et al.
NATURE REVIEWS IMMUNOLOGY (2008)
Practical methods for incorporating summary time-to-event data into meta-analysis
Jayne F. Tierney et al.
TRIALS (2007)
Molecular portraits of human breast tumours
CM Perou et al.
NATURE (2000)
Share Paper
